Wrocław, Poland, December 15, 2021 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of protein degradation drugs for cancer and autoimmune diseases, today announces that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.
Please register for the event and confirm your interest in meeting with Captor Therapeutics management here.
The LifeSci Partners Corporate Access Event will feature innovative publicly traded and privately held biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe. The event will include meetings with company senior management teams and panel discussions featuring KOLs, CEOs, specialized investors, and healthcare experts, highlighting the most relevant topics impacting today’s life sciences industry.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
LinkedIn: @CaptorTherapeutics
Twitter: @CaptorTherapeu1
For further information, please contact:
|
Polish Media and Investor relations: Point of View Jakub Radzewicz +48 601 155 582
|
International Investor Relations: LifeSci Advisors Guillaume van Renterghem +41 (0)76 735 01 31 gvanksy2jrenterghem@lifesciadvisors.com |
